종양괴사인자 저해제 시장 : 기회, 성장 촉진요인, 산업 동향 분석과 예측(2024-2032년)

The Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market was valued at USD 41.3 billion in 2023 and is projected to grow at a CAGR of 2.2% from 2024-2032. The market's growth is largely attributed to the increasing incidence of autoimmune diseases such as psoriasis, rheumatoid arthritis, and inflammatory bowel disease. As awareness and diagnostic capabilities for these conditions improve, the demand for effective treatment options has risen significantly. TNF inhibitors, known for their efficacy in controlling symptoms of chronic inflammatory diseases, have become a key component in treatment protocols.

The overall tumor necrosis factor inhibitor drugs industry is classified based on the drug class, indication, route of administration, distribution channel, and region.

The tumor necrosis factor inhibitor drugs market is categorized by drug class into certolizumab pegol, adalimumab, infliximab, etanercept, and golimumab. In 2023, the adalimumab segment led the market, commanding a valuation of USD 24.2 billion. Adalimumab, a monoclonal antibody with a focus on tumor necrosis factor (TNF), boasts a significant market share in the TNF inhibitor drugs arena, thanks to its broad efficacy, commendable safety profile, and prevalent use across various autoimmune diseases. The continuous development of novel formulations and delivery methods bolsters its market presence.

Segmented by indication, the tumor necrosis factor inhibitor drugs market includes hidradenitis suppurativa, rheumatoid arthritis, psoriatic arthritis, psoriasis, Crohn's disease, ankylosing spondylitis, ulcerative colitis, juvenile idiopathic arthritis, and other conditions. In 2023, the rheumatoid arthritis segment led the market with a 42.0% share. Rheumatoid arthritis (RA) is a chronic inflammatory disorder primarily impacting joints, leading to pain, swelling, and potential joint damage, resulting in a significant patient population seeking effective treatment. The rising prevalence of RA, combined with heightened awareness and diagnostic rates, has spurred the demand for TNF inhibitors in RA treatment.

In 2023, North America led the global tumor necrosis factor inhibitor drugs market with revenues reaching USD 17 billion, and projections suggest it could hit USD 20 billion by 2032. The region's leadership is largely due to the presence of top-tier pharmaceutical and biopharmaceutical companies, which are at the forefront of developing innovative TNF inhibitors. North America's strong healthcare system, paired with established regulatory pathways, ensures swift market entry and acceptance of new therapies. Heightened patient awareness and access to cutting-edge treatment options solidify North America's dominant stance in the global TNF inhibitor drugs market.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of autoimmune diseases
    • 3.2.1.2 Expansion of therapeutic indications
    • 3.2.1.3 Advancements in biotechnology and drug development
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of treatment
    • 3.2.2.2 Side effects and safety concerns
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Patent analysis
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Adalimumab
  • 5.2.1 Branded
  • 5.2.2 Biosimilar
• 5.3 Etanercept
  • 5.3.1 Branded
  • 5.3.2 Biosimilar
• 5.4 Infliximab
  • 5.4.1 Branded
  • 5.4.2 Biosimilar
• 5.5 Golimumab
• 5.6 Certolizumab pegol

Chapter 6 Market Estimates and Forecast, By Indication, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Rheumatoid arthritis
• 6.3 Psoriasis
• 6.4 Psoriatic arthritis
• 6.5 Crohn's disease
• 6.6 Ulcerative colitis
• 6.7 Ankylosing spondylitis
• 6.8 Juvenile idiopathic arthritis
• 6.9 Hidradenitis suppurativa
• 6.10 Other indications

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Subcutaneous injection
• 7.3 Intravenous injection

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital pharmacies
• 8.3 Retail pharmacies
• 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 AbbVie Inc.
• 10.2 Amgen Inc.
• 10.3 Boehringer Ingelheim Pharmaceuticals, Inc.
• 10.4 Bio-Thera Solutions, Ltd.
• 10.5 Janssen Biotech, Inc.
• 10.6 Merck and Co., Inc.
• 10.7 Pfizer Inc.
• 10.8 Samsung Bioepis Co., Ltd.
• 10.9 Sandoz Group AG
• 10.10 UCB, Inc.